MHRA grants approval for RXC004 trial restart

22nd January 2019 Uncategorised 0

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has given formal approval for Redx Pharma to re-commence a Phase I/IIa trial of experimental cancer therapy RXC004.

More: MHRA grants approval for RXC004 trial restart
Source: News